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ABSTRACT
Objective
The cost-effectiveness of oxaliplatin in combination 
with 5-fluorouracil/leucovorin (5fu/lv)—the folfox 
regimen—was compared with that of 5fu/lv alone 
as adjuvant therapy for patients with stage iii colon 
cancer, from the perspective of the Cancer Care 
Ontario New Drug Funding Program. In the mosaic 
(Multicenter International Study of Oxaliplatin/5-
Fluorouracil/Leucovorin in the Adjuvant Treatment of 
Colon Cancer) trial, the folfox regimen significantly 
improved disease-free survival. The  mosaic trial 
formed the basis of the present analysis.
Methodology
Extrapolated patient-level data from the mosaic trial 
were used to model patient outcomes from treatment 
until death. Utilities were obtained from the litera-
ture. Resource utilization data were derived from the 
mosaic trial and supplemented with data from the 
literature. Unit costs were obtained from the Ontario 
Ministry of Health and Long-Term Care, the London 
Health Sciences Centre, and the literature.
Results
Lifetime incremental cost-effectiveness ratios for 
folfox compared with 5fu/lv were CA$14,266 per 
disease-free year, CA$23,598 per life-year saved, 
and CA$24,104 per quality adjusted life-year (qaly) 
gained, discounting costs and outcomes at 5% per an-
num. These results were stable for a wide range of in-
puts; only utility values associated with relapse seemed 
to influence the cost-effectiveness ratios observed.
Conclusions
With an incremental cost of CA$24,104 per  qaly 
gained, folfox is a cost-effective adjuvant treatment 
for stage iii colon cancer. Compared with 5fu/lv 
alone, this regimen offers better clinical outcomes 
and provides good value for money.
KEY WORDS
Oxaliplatin, cost-effectiveness, adjuvant, chemo-
therapy, colon cancer, 5fu/lv
1.  INTRODUCTION
Colorectal cancer includes cancers of both the colon 
and the rectum, and is the most common form of 
gastrointestinal cancer. In Canada, colorectal cancer is 
the fourth most common cancer in terms of incidence 
rates, both sexes combined, and second only to lung 
cancer as a cause of cancer death 1. With estimated 
age-standardized incidence rates for 2009 of 62 and 
41 per 100,000 for men and women respectively, 
colorectal cancer is expected to develop in 1 in every 
14 men and 1 in every 16 women during their lifetime, 
with 1 in 27 men and 1 in 31 women dying from the 
disease 1. In 2009, an estimated 22,000 Canadians 
will be diagnosed with colorectal cancer, and 9100 
will die 1. A recent Canadian analysis 2 noted that any 
modest decreases in incidence and mortality rates are 
more than offset by the increasing numbers of new 
cases attributable to the aging population. There is 
thus no sign of the burden of colorectal cancer abat-
ing. With so many at risk, effective treatments for 
colon cancer are critical.
In 2007, based on results of the mosaic (Multi-
center International Study of Oxaliplatin/5-Fluorou-
racil/Leucovorin in the Adjuvant Treatment of Colon 
Cancer) study, Health Canada approved oxaliplatin 
(Eloxatin: Sanofi–Aventis Canada Inc., Laval, QC) 
in combination with 5-fluorouracil/leucovorin (5fu/
lv) as adjuvant treatment in patients with stage iii 
colon cancer.
In  mosaic, a large international randomized 
phase iii trial (146 centres), the folfox4 regimen 
(oxaliplatin/5fu/lv, hereinafter “folfox”) was 
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compared with 5fu/lv alone in patients with stage ii 
or iii colon cancer 3. At a median follow-up of 3 
years, the addition of oxaliplatin reduced the risk 
of recurrence by 23% in stage ii and iii patients who 
had undergone surgery for their primary tumour and 
by 24% in the subset of stage iii patients. After 77 
months of follow-up, this benefit in stage iii patients 
was confirmed at the 5-year mark (22% risk reduc-
tion in relapse or disease recurrence) 4. At a median 
follow-up of 6 years, a 20% reduction in risk of death 
was observed in stage iii colon cancer patients 5. 
Furthermore, as of the January 2007 cut-off update, 
significant benefits in overall survival (os) were also 
seen in the intention-to-treat (itt) population 5. These 
results support folfox as the current standard for 
adjuvant therapy in colon cancer 6. In fact, based on 
a review of colon cancer patient charts conducted 
for cases resected in 2007–2008 for Cancer Care 
Ontario (cco), folfox was the chemotherapy agent 
most commonly used in Ontario, with 78.6% of 
patients treated outside of clinical trials receiving 
this regimen 7.
Currently, folfox is reimbursed for stage iii colon 
cancer in all Canadian provinces. Ontario and British 
Columbia further reimburse it in high-risk stage ii co-
lon cancer and in rectal cancer. Decisions to fund are 
based on not only the clinical benefit of a product, but 
also whether the product provides reasonable value 
in terms of clinical benefit for the cost of treatment. 
The cost–utility analysis (cua) presented here was 
conducted to determine the value—in terms of the 
incremental costs per life-year (ly) gained and per 
quality-adjusted life-year (qaly) gained—of oxalip-
latin as used in the folfox regimen, compared with 
infusional 5fu/lv alone, for the adjuvant therapy of 
patients with completely resected stage iii (Dukes C) 
colon cancer. In October 2008 in Ontario, the recom-
mendations of the Committee to Evaluate Drugs to 
fund oxaliplatin were based, in part, on the results 
reported here 6.
2.  METHODS
2.1  Study Design
The cua compared oxaliplatin in combination with 
5fu/lv administered per the folfox4 regimen against 
5fu/lv alone, using data at the level of the individual 
patient from the previously reported mosaic trial 3. 
The mosaic phase  iii trial included 2246 patients 
with stage ii (40%) and iii (60%) colon cancer whose 
tumours had been completely surgically removed. 
The primary trial endpoint was disease-free survival 
(dfs) at 3 years. Secondary trial endpoints included 
toxicity and os. Outcomes were analyzed based on 
the itt population. Patients were randomized to re-
ceive 5fu/lv or folfox every 2 weeks for 12 cycles 
as defined in the mosaic trial and recommended by 
cco guidelines 8.
For several reasons, including the fact that ran-
domized trials are typically of short duration, cuas 
often combine data taken from randomized trials with 
the use of decision analytic modelling. Similarly, the 
present analysis derived estimates of clinical effec-
tiveness (dfs and os) and resource use from the mosaic 
trial and extrapolated the clinical benefits and costs 
specific to each regimen over the lifetime (50 years) 
of the patient cohort.
The primary outcome measure chosen for this 
economic evaluation was the qaly; however, disease-
free years (dfys) and lys gained are also reported. The 
qaly reflects os, adjusted by health-related quality of 
life. To calculate qalys, life-years are multiplied by 
utility values that represent preference-based values 
for health states. Utility values vary depending on 
age, sex, and the occurrence of relapse or adverse 
events. Because utility values were not collected in 
the mosaic trial, these estimates were derived from 
the available literature.
The analysis included disease-related health care 
costs from the perspective of the Ontario Ministry 
of Health and Long-Term Care. Resource utiliza-
tion data were derived from the  mosaic trial, and 
unit costs were derived from the Ontario Ministry 
of Health and Long-Term Care, the London Health 
Sciences Centre, and the published literature. Costs 
and outcomes were discounted to present values at a 
rate of 5% per year 9.
To test the robustness of the base-case results to 
variations in input parameters and assumptions, one-
way sensitivity analyses were performed on discount 
rates, utility values, the choice of time horizon, and 
patient population (stages ii and iii).
2.2  Patient Population
The inclusion criteria for patients in the mosaic trial 
have been published 3. To summarize, patients were 
between 18 and 75 years of age and had undergone 
complete surgical resection of histologically proven 
stage ii (T3 or T4, N0, M0) or stage iii (any T, N1 or 
N2, M0) colon cancer. For our base case analysis, only 
patients with stage iii colon cancer were considered.
2.3  Treatment Regimens
Treatment commenced no later than 7 weeks post surgery. 
Patients were randomized to these treatment groups:
●    5fu/lv group: (given on both days 1 and 2 every 
14 days for 12 cycles) a 2-hour infusion of lv 
200 mg/m2, followed by a bolus of 5fu 400 mg/
m2, followed by a 22-hour protracted infusion of 
5fu 600 mg/m2
●  folfox group: exactly the same as for the 5fu/lv 
group, except that a 2-hour infusion of oxaliplatin 
85 mg/m2 is given simultaneously with the 2-hour 
infusion of lv 200 mg/m2 on day 1 only19
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2.4  Effectiveness Assessment
Treatment effectiveness was summarized in terms 
of qalys so as to capture survival as well as health-
related quality of life.
2.4.1  Survival
The primary endpoint of the mosaic trial was dfs. The 
median period of follow-up in that trial was 44.2 months 
at the time that the present economic evaluation was de-
veloped. Patient-level data regarding os was, therefore, 
derived directly from the mosaic trial for 4 years and 
was extrapolated to a lifetime horizon. The os for a full 
lifespan was derived by extrapolating the dfs trial data. 
The method of extrapolation has been described in full 
detail in Aballéa et al. 2007 10. In brief, it was assumed 
that survival of patients in the first 4 years matched 
the experience of the participants in the mosaic trial. 
Survival beyond year 4 and to the end of year 5 was 
extrapolated using Weibull distributions, and survival 
beyond year 5 was assumed to match survival in the 
general population as observed in standard Canadian life 
tables 11. This final assumption required no recurrences 
of colon cancer beyond 5 years from diagnosis.
2.4.2  Quality of Life and Health Utility
The cua uses the qaly as a composite measure that 
combines the length of a patient’s life with the quality 
of life that the patient experiences, where quality of 
life is measured on a 0 to 1 health utility scale. For 
example, 5 years at perfect health (utility 1) is worth 5 
qalys; 5 years in poor health (for example, utility 0.5) is 
worth 2.5 qalys. To conduct the cua, estimates of util-
ity were required for disease-free patients with stage iii 
colon cancer, and for relapsed patients with stage iii 
colon cancer. Disutilities associated with chemotherapy 
toxicities were also incorporated into the analysis.
Utility Associated with “Disease-free” Stage III Co-
lon Cancer:  Based on the studies of van den Brink 
et al. 12 and Ness et al. 13, the utility values for stage iii 
colon cancer patients diagnosed with the disease or 
surviving disease-free were in the range 0.63–0.89. A 
midpoint value of 0.76 was chosen, meaning that each 
patient entered the model with a utility of 0.76. For 
patients who remained “disease-free,” annual utility 
from baseline to year 5 was adjusted to account for 
declining health as a consequence of aging.
Patients who remained disease-free for 5 years 
were considered “cured,” and their utility was set to 
that of the general population (specific to the age and 
sex of the patient).
Utility Associated with Relapsed Stage III Colon 
Cancer:  Based again on the studies of van den 
Brink et al. 12 and Ness et al. 13, utility values for 
relapse were reported to be in the range 0.24–0.67. 
We therefore assumed a midpoint value of 0.45 in the 
base-case analysis for patients with relapsed colon 
cancer. The patient’s annual utility declined from that 
point forward, until death, to account for aging.
Utility Associated with Chemotherapy Toxici-
ties:  Finally, utility decrements were incorporated 
into the model for the proportion of patients experi-
encing the following types of chemotherapy-related 
toxicities: grades 3 and 4 neutropenia, grades 2–4 
neuropathy, grades 2–4 nausea and vomiting, and 
grades 2–4 diarrhea. The proportion of patients 
experiencing these toxicities was derived from the 
mosaic study. Estimates of utility associated with 
chemotherapy-related toxicities in colon cancer were 
not available in the literature. Accordingly, utility 
reductions associated with adverse events occurring 
following chemotherapies for other cancers were 
extracted from the literature. The utility decrements 
used in our model were previously detailed by Aballéa 
et al. 10 in the U.S. cost-effectiveness analysis.
2.5  Costs and Resource Utilization
Resource utilization data were derived from the mo-
saic trial, supplemented with data from the literature 
and validated using expert opinion at the Ottawa 
Hospital Regional Cancer Centre. Unit costs were 
derived from the London Health Sciences Centre, 
the Ontario Ministry of Health and Long-Term Care, 
relevant Web sites such as the cco site, and the pub-
lished literature. The types of costs included were 
study chemotherapy, pre-treatment medications, re-
placement chemotherapy in the presence of toxicities, 
serious and non-serious adverse events, disease and 
toxicity within the trial, and costs of relapses. Costs 
are reported in 2006 Canadian dollars (CA$).
2.5.1  Costs of Study Chemotherapy
The costs associated with study chemotherapy includ-
ed the costs of the 6-month course of treatment with 
either folfox or 5fu/lv. These costs were calculated 
using the doses actually administered in the mosaic 
trial. The cost for 5fu/lv was taken from the cco Drug 
Formulary in November 2006 8, which reported that 
cost to be CA$19 per cycle. Oxaliplatin is used at a 
dose of 85 mg/m2, and thus, for a patient with a body 
surface area of 1.75 m2, the cost per cycle of oxalip-
latin used in the model was CA$1487 14.
In addition to drug acquisition costs, “study che-
motherapy costs” included the costs associated with 
drug administration, including inpatient or outpatient 
visit, infusion pump, insertion of a peripheral catheter 
line, pharmacy costs, and nursing costs. The only dif-
ference in costs between the two arms was the extra 
time required to administer the oxaliplatin, and a 
slightly higher estimate of the pharmacy fee.
2.5.2  Costs of Pre-Treatment Medications
In addition to study chemotherapy, patients are 
often provided with prophylactic medications for 20
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chemotherapy-induced side effects. It was assumed 
that patients received oral ondansetron 8 mg twice 
daily for 3 days and intravenous dexamethasone 
(8 mg/mL).
2.5.3  Costs of Adverse Events
For each serious adverse event reported in the trial, the 
corresponding costs (based on codes in the Internation-
al Statistical Classification of Diseases and Related 
Health Problems, 10th revision 15) were collected from 
a data abstraction through the London Health Sciences 
Centre. Table i outlines the serious adverse event costs 
incorporated into the model. Table ii outlines the costs 
of non-serious adverse events. The folfox regimen was 
associated with higher levels of adverse events than 
were seen with 5fu/lv, including significant differences 
in neutropenia (with and without fever or infection), 
thrombocytopenia, paresthesia, nausea and vomiting, 
diarrhea, and allergic reactions 3.
2.5.4  Costs of Disease and Toxicity Monitoring Within 
the Trial
The costs of disease monitoring included outpatient 
visits such as follow-up visits, laboratory tests (for 
example, platelets, hemoglobin, neutrophils, biliru-
bin, serum glutamic oxaloacetic transaminase, serum 
glutamic pyruvic transaminase, alkaline phosphatase, 
carcinoembryonic antigens) and radiologic evalu-
ations (for example, chest radiography, abdominal 
ultrasonography, abdominopelvic computerized 
tomography) and colonoscopies.
2.5.5  Costs of Relapse
The treatment of relapse was assumed to be inde-
pendent of the study treatment arm. A 2003 study 
by Maroun et al. 16 estimated the direct health care 
costs associated with the lifetime management of 
patients with a diagnosis of colon and rectal cancer 
in Canada. Of the 487 patients that relapsed in the 
mosaic trial, 19% had local recurrences and 81% had 
metastatic recurrences.
2.6  Sensitivity Analysis
Our base-case analysis compared the folfox regimen 
with 5fu/lv in stage iii colon cancer patients over a 
lifetime horizon. To assess the robustness of our re-
sults to changes in input parameters and assumptions, 
one-way sensitivity analyses were run according to 
these scenarios:
●  Utility values associated with chemotherapy-related 
toxicities were varied by plus or minus 20%.
●  Utility values associated with relapse were altered to 
0, 0.24, and 0.67 (the base-case assumption was 0.45).
●  Utility values associated with hospitalization 
were varied from 0% to 100% decrement when 
the base case was set at a 50% decrement.
A sensitivity analysis was also conducted that 
considered the full patient population of the mosaic 
study, including both stage ii and stage iii patients. 
table i  Costs of serious adverse events
iCd-10 code Description Length  
of stay
(days)
Cost  
per case 
(2006 CA$)
R50 Fever 4.02 4,304
T88.7 Allergic reaction 1 1,438
K52.9 Diarrhea 7.95 8,355
J13–J18.9 Pneumonia 7.97 7,581
D70 Neutropenic sepsis 6.26 7,285
R11.1, R11.2, 
R11.3
Nausea and vomiting 3.64 2,969
I80.2 Deep leg  
thrombophlebitis
9.00 6,754
078 Pulmonary embolism 6.30 6,676
R10 Abdominal pain 2.6 2,390
K56.6 Intestinal obstruction 9.7 11,529
T80 Injection site reaction 3.0 3,305
icd-10 = International Statistical Classification of Diseases and 
Related Health Problems, 10th revision 16.
table ii  Costs of non-serious adverse events
Description Treatment assumption Cost per case
(2006 CA$)
Nausea and vomiting 10.76/episode
Grade 2 Prochlorperazine (10 mg) in combination with
oral dexamethasone (4 mg), 4 times daily for 3 days
Grades 3 and 4 Intravenous prochlorperazine and
oral dexamethasone (8 mg) for 3 days
13.12/episode
Neutropenia
Grade 2 No treatment 0
Grades 3 and 4 Admitted to hospital 5197
Diarrhea Loperamide (16 mg daily for 12 days);
stool culture and test for Clostridium difficile
25.7521
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Finally, a sensitivity analysis was conducted that 
considered a 4-year time horizon (the duration of 
follow-up in the mosaic study).
3.  RESULTS
3.1  Effectiveness
Figure 1 summarizes the dfs and os differences 
between the two regimens at 4 years (within-
trial), between 4 and 5 years, and extrapolated to   
50 years.
During the initial 4-year follow-up, 194 pa-
tients treated with folfox either relapsed or died, 
compared with 245 patients treated with 5fu/lv 
alone 17. The Kaplan–Meier analysis of the  mo-
saic trial predicted that 69.1% of patients in the 
oxaliplatin arm would be disease-free at 4 years 
compared with 60.7% of patients in the 5fu/lv arm 
(log-rank test: p = 0.002). Within-trial dfs and os 
translated into gains, with discounting, of 0.192 
dfys and 0.054 lys for folfox-treated patients, as 
shown in Table iii.
By using a Weibull extrapolation to fit the model 
to the tail end of the within-trial survival curve, dfs 
and os were extrapolated from 4 years to 5 years (60 
months). The gains observed between the 4-year and 
5-year time periods were added to the improvements 
observed up to 4 years, resulting in differences in 
favour of oxaliplatin of 0.262 and 0.085 in dfys and 
lys respectively.
Using Canadian life tables to extrapolate the os 
and dfs curves, with discounting, total accruals for 
folfox-treated patients were 1.08 and 0.653 in dfys 
and lys respectively.
3.2  Cost Outcomes
As illustrated in Table iv, the largest contributor to 
total cost for each treatment arm was chemotherapy, 
at CA$15,665 for folfox and CA$1757 for 5fu/lv 
(incremental difference: CA$13,908). The cost of the 
chemotherapy was based on the actual chemotherapy 
administered in the mosaic trial. The planned 12 
figure 1  Within-trial and extrapolated survival differences over time. OS = overall survival; DFS=disease-free survival; FOLFOX = folinic 
acid, 5-fluorouracil, oxaliplatin; 5FU/LV = leucovorin/5-fluorouracil
table iii  Incremental health outcomes, discounted by 5%
Time horizon Outcome fOlfOx 5fu/lV Difference
4 Years dfys 3.042 2.850 0.192
lys 3.372 3.318 0.054
qalys 2.440 2.373 0.067
5 Years dfys 3.605 3.343 0.262
lys 4.003 3.917 0.085
qalys na na na
50 Years dfys 9.861 8.781 1.080
lys 10.418 9.765 0.653
qalys 8.048 7.409 0.639
folfox = folinic acid, 5-fluorouracil, oxaliplatin; 5fu = 5-fluorouracil; 
lv = leucovorin; dfys = disease-free years; lys = life-years; qalys = 
quality-adjusted life-years; na = not available.22
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cycles of adjuvant therapy were received by 86% of 
patients in the 5fu/lv group and 75% of patients in the 
folfox group. The median relative dose intensity of 
5fu received was 84% for the folfox group and 98% 
for the 5fu/lv group. Costs associated with relapse on 
treatment and relapse during follow-up were lower 
with the folfox regimen. However, higher drug acqui-
sition costs for folfox and costs associated with treat-
ing chemotherapy-related toxicities were major cost 
drivers, resulting in an incremental cost of CA$15,409 
for folfox patients over a lifetime horizon.
3.3  Cost-Effectiveness
The base-case analysis demonstrated that adjuvant 
chemotherapy was more effective with folfox than 
with 5fu/lv, but it was also more costly. The lys and 
qalys were higher because of greater dfs and os in 
the folfox arm as compared with the arm using 5fu/
lv alone. Table v shows cost per ly saved and cost per 
qaly gained for folfox as compared with 5fu/lv.
3.4  Sensitivity Analyses
A number of sensitivity analyses were conducted 
to evaluate the robustness of the base-case results. 
Most of the sensitivity analyses had little effect on 
the results. Interestingly, including stage ii patients 
from the mosaic trial still resulted in a cost per qaly 
of CA$33,534 over a lifetime horizon. However, as 
expected, limiting the analysis to 4 years resulted in 
a cost-effectiveness ratio for stage iii patients of more 
than CA$200,000 per qaly gained.
There are concerns with the external validity of 
the utility estimates, but the estimates used in the 
base-case analysis represent the best available data. 
Uncertainty in connection with the utility decrement 
associated with relapse had a large impact on the 
results of the within-trial analysis (for example, the 
4-year time horizon); however, the effect of this pa-
rameter on the long-term results is modest. The incre-
mental cost-effectiveness ratio (icer) was CA$30,402 
when no utility decrement associated with relapse was 
assumed; that figure decreased to CA$21,138 when 
a 0.24 utility for a relapse was estimated.
4.  DISCUSSION
After a complete surgical resection (undertaken with 
curative intent), patients with stage iii colon cancer 
have a 50%–60% chance of developing recurrent 
disease 18. New therapies that improve dfs in these 
patients, such as folfox, are thus vital. Based on the 
mosaic study, we therefore analyzed the cost-effec-
tiveness of the folfox regimen in stage iii patients.
Cost-effectiveness analysis using qalys permits 
funding agencies to consider the value of alternative 
therapies, taking into account costs in addition to both 
quantity and quality of survival. Although patients on 
folfox had a greater incidence of toxicities than did 
those on 5fu/lv, the negative effect of the toxicities 
on qalys was outweighed by the qalys gained from 
improved survival with folfox. The gain in qalys 
was obtained at a reasonable cost-per-qaly ratio of 
CA$24,104.
The results from our evaluation appear to be very 
similar to the U.S. cost-effectiveness results presented 
by Aballéa et al. 10 After discounting costs and out-
comes at 3% per annum, the U.S. evaluation reported 
an icer of US$20,600 per ly gained and US$22,800 
per qaly gained. Likewise, the analysis submitted 
to the National Institute for Clinical Excellence by 
Sanofi–Aventis U.K. presented a cost–utility ratio 
of ₤4805 per qaly gained over a lifetime horizon 18. 
table iv  Disaggregated within-trial and beyond-trial costs in 2006 
Canadian dollars, discounted by 5%
Cost category Costs
fOlfOx 5fu/lV Incremental
Within-trial costs
Study chemotherapy 15,665 1,757 13,908
Outpatient visits 638 661 –23
Lab tests 236 244 –8
Radiologic evaluations 1,837 1,889 –52
Neutropenia 2,553 226 2,328
Neuropathy 0 0 0
Diarrhea 13 11 2
Nausea and vomiting 10 3 6
Serious adverse events 1,677 1,041 636
Relapse treatment 3,074 4,175 –1,100
Relapse follow-up 429 618 –189
TOTAL 26,133 10,623 15,509
Beyond-trial costs
Relapse 200 297 –97
Follow-up 1,106 998 108
Other 287 398 –111
LIFETIME TOTAL 27,726 12,317 15,409
folfox = folinic acid, 5-fluorouracil, oxaliplatin; 5fu = 5-fluorouracil; 
lv = leucovorin.
table v  Cost–utility analysis
Costs
(2006 CA$)
dfys lys qalys
Regimen
folfox 27,726 9.861 10.418 8.048
5fu/lv 12,317 8.781 9.765 7.409
Incremental 15,409 1.080 0.653 0.639
icera 14,266 23,598 24,104
dfy = disease-free years; ly = life-years; qaly = quality-adjusted 
life-years;  folfox = folinic acid, 5-fluorouracil, oxaliplatin; 
5fu = 5-fluorouracil; lv = leucovorin; icer = incremental cost-
effectiveness ratio.23
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Comparing the qaly estimates, the Canadian and 
the U.K. models were very similar, with incremen-
tal differences between the two arms of 0.68 in the 
U.K. model and 0.639 in the Canadian model. The 
differences resulted from the use of different discount 
rates in the two analyses and also from some updated 
utility estimates that were available for the Canadian 
analysis. The results were higher in Canada and the 
United States as compared with the United King-
dom because of the relative difference in the price 
of oxaliplatin as compared with 5fu/lv between the 
countries. In the same disease setting, the estimated 
cost per ly gained for capecitabine as compared with 
5fu/lv was £3899 (after discounting at 3.5% for costs 
and outcomes) 19.
A limitation of the mosaic trial data in informing 
this economic analysis is that mosaic was not designed 
for such purposes and was not powered to detect a 
significant difference in os. The dfs data from the 
mosaic trial was used to calculate recurrence rates—
and ultimately to estimate survival. Thus, the value 
of dfs as a predictor of longer-term os is key to this 
analysis. The literature suggests that this predictive 
power holds, because a meta-analysis of clinical trials 
on adjuvant colon cancer has shown that dfs at 3 years 
is a strong predictor of os at 5 years 20. Moreover, 
since the time of the original evaluation, the mosaic 
trial investigators have published 6-year os data 5. We 
were thus able to test the predictive validity of the 
model at the 6-year time point. For stage iii patients, 
the os reported was 72.9% for folfox and 68.7% for 
5fu/lv 5. The model predicted 71.4% for folfox and 
67.1% for 5fu/lv. These results illustrate that, at the 
6-year point, the model was within 1.5% of the actual 
os observed in the trial.
Another limitation is that many of the resource 
utilization estimates were informed from the trial. 
Should some of the resource utilization have been 
protocol-driven, then resource utilization in our analy-
sis may have been overestimated. In an attempt to 
correct for this possibility, we held consultations with 
clinicians to ensure that assumptions in our analysis 
reflected current practice.
Finally, the availability of relevant utility values 
for the calculation of qalys was limited. We believe 
that the evaluation presented here used the best 
available data; the results of the sensitivity analysis 
suggest that the effect of this parameter on long-term 
results is modest.
Based in part on the information presented in the 
present economic evaluation, the province of Ontario 
recommended that oxaliplatin in combination with 
5fu/lv (folfox) be funded for the adjuvant treatment 
of colon cancer. Based on the biologic similarities 
between colon and rectal cancer, the provinces of 
Ontario and British Columbia have both extended 
their funding to include rectal cancer. Within the 
clinical community, the strong evidence put forward 
by the Intergroup N9741 study 21 and by the mosaic 
trial have led to oxaliplatin being part of the standard 
of care of colorectal cancer in Canada.
5.  CONCLUSIONS
The analysis presented here demonstrates that adding 
oxaliplatin to 5fu/lv in the adjuvant setting in patients 
with stage iii colon cancer represents a cost-effective 
use of resources.
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